Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $1.9 million.

  • Keros Therapeutics' Capital Expenditures fell 65.80% to $132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 21.85%. This contributed to the annual value of $1.9 million for FY2024, which is 21.63% down from last year.
  • As of FY2024, Keros Therapeutics' Capital Expenditures stood at $1.9 million, which was down 21.63% from $2.5 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Capital Expenditures peaked at $2.5 million during FY2023, and registered a low of $294,000 during FY2020.
  • Moreover, its 3-year median value for Capital Expenditures was $1.9 million (2024), whereas its average is $1.9 million.
  • Per our database at Business Quant, Keros Therapeutics' Capital Expenditures surged by 248.30% in 2021 and then declined by 21.63% in 2024.
  • Over the past 5 years, Keros Therapeutics' Capital Expenditures (Yearly) stood at $294,000 in 2020, then spiked by 248.30% to $1.0 million in 2021, then grew by 21.19% to $1.2 million in 2022, then surged by 98.55% to $2.5 million in 2023, then fell by 21.63% to $1.9 million in 2024.